Stock BHC BAUSCH HEALTH COMPANIES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Bausch Health Companies Inc. Stock Toronto S.E.

Equities

BHC

CA0717341071

Pharmaceuticals

Market Closed - Toronto S.E.
Other stock markets
 03:59:59 2024-05-31 pm EDT 		5-day change 1st Jan Change
8.96 CAD +4.31% Intraday chart for Bausch Health Companies Inc. +2.76% -15.80%
May. 23 Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada MT
May. 17 Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 CI

Financials

Sales 2024 * 9.4B 12.8B Sales 2025 * 9.67B 13.17B Capitalization 2.41B 3.28B
Net income 2024 * 148M 202M Net income 2025 * 389M 530M EV / Sales 2024 * 2.43 x
Net Debt 2024 * 20.44B 27.85B Net Debt 2025 * 19.09B 26.01B EV / Sales 2025 * 2.22 x
P/E ratio 2024 *
19.5 x
P/E ratio 2025 *
6.23 x
Employees 20,270
Yield 2024 *
-
Yield 2025 *
-
Free-Float 97.54%
More Fundamentals * Assessed data

Chart Bausch Health Companies Inc.

Dynamic Chart

Latest news about Bausch Health Companies Inc.

Bausch Health Announces Wider Public Drug Plan Coverage for Uceris in Canada MT
Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 CI
RBC Notes Updates on Bausch Xifaxan Patent Litigation with Norwich MT
Bausch Health Companies Inc. Approves Directorate Appointments CI
Bausch Health Down 6.6% In US After Hours As Updates Related to Norwich XIFAXAN Matters MT
Bausch Health Brief: Announcing Updates Related to Norwich XIFAXAN Matters MT
RBC Noes Bausch Health Filing For Rehearing in Appellate Court MT
RBC Lowers Bausch Health Target to US$10, Maintains Sector Perform MT
Bausch Health Shares Fall Following Q1 Results MT
Bausch Health Q1 Net Loss Narrows on Higher Revenue, Confirms 2024 Revenue Guidance MT
Transcript : Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024
Bausch Health Brief: Reaffirmed full-year Revenue and Adjusted EBITDA (non-GAAP) guidance MT
Bausch Health Brief: Q1 revenues of US$2.15 billion, up 11% on a Reported and 8% on an Organic basis MT
Bausch Health Companies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
North American Morning Briefing : Stock Futures -2- DJ
More news

Latest transcript on Bausch Health Companies Inc.

Logo Bausch Health Companies Inc.
Bausch Health Companies Inc., Q1 2024 Earnings Call, May 02, 2024
More transcripts

Analyst Recommendations on Bausch Health Companies Inc.

RBC Trims Price Target on Bausch Health to $11 From $12, Keeps Sector Perform Rating MT
Bausch Health's Issuer Credit Rating Upgraded by S&P MT
Trump eyes $43 million haul from biggest fundraiser yet RE
RBC Ups PT on Bausch Health Companies to $12 From $9 Reflecting Upcoming Appellate Court Decisions & Potential BLCO Distribution, Maintains Sector Perform Rating MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
More recommendations

Press releases Bausch Health Companies Inc.

Bausch Health Companies - Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024 AQ
Bausch Health Announces 2024 Annual Meeting of Shareholder Results AQ
Bausch Health Announces First Quarter 2024 Results AQ
Bausch: Q1 Earnings Snapshot AQ
Bausch Health, Canada Inc. - Acne vulgaris treatment PrARAZLO now available to patients through British Columbia PharmaCare public drug plan AQ
More press releases

News in other languages on Bausch Health Companies Inc.

Insider - Milliardäre sammelten Geld für Trumps Sicherheitsleistung
Bausch Health Companies Inc.: KORREKTUR DURCH QUELLE: Thermage(R) FLX und TR-4 Return Pad von Solta Medical erhalten Registrierungszertifikate in China
KKR : signe un accord de financement avec Bausch Health
Citadel : l'hedge da record, 16 miliardi di dollari di utili (MF)
Bolsa de Madrid: ¿Culpa o no culpa?
More news

Quotes and Performance

1 day+4.19%
1 week+2.76%
1 month-25.73%
3 months-29.91%
6 months-7.54%
Current year-15.80%
More quotes

Highs and lows

1 week
8.32
Extreme 8.32
8.96
1 month
8.32
Extreme 8.32
12.06
Current year
8.32
Extreme 8.32
15.43
1 year
8.32
Extreme 8.32
15.43
3 years
5.10
Extreme 5.1
38.96
5 years
5.10
Extreme 5.1
43.97
10 years
5.10
Extreme 5.1
347.84
More quotes

Managers and Directors - Bausch Health Companies Inc.

Managers TitleAgeSince
Thomas Appio CEO
 Chief Executive Officer 61 -
John Barresi DFI
 Director of Finance/CFO 51 22-05-23
Mirza Dautbegovic COO
 Chief Operating Officer - -
Members of the board TitleAgeSince
Robert Power BRD
 Director/Board Member 67 08-07-31
John Paulson CHM
 Chairman 68 17-05-31
Steven Miller BRD
 Director/Board Member 35 21-03-16
More insiders

Quotes

Date Price Change Volume
24-05-31 8.95 +4.19% 794,180
24-05-30 8.59 +2.14% 273,742
24-05-29 8.41 -0.59% 253,077
24-05-28 8.46 -0.59% 396,718
24-05-27 8.51 -2.30% 141,873

Delayed Quote Toronto S.E., May 31, 2024 at 03:59 pm EDT

More quotes

Company Profile

Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
Sector
Pharmaceuticals
Calendar
2024-08-05 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Bausch Health Companies Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
6.56 USD
Average target price
9.786 USD
Spread / Average Target
+49.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BHC Stock
  4. BHC Stock